EIP Pharma announces positive results with neflamapimod in two Phase IIa clinical trials of Alzheimer's disease

EIP Pharma has secured proof-of-mechanism for neflamapimod (previously named VX-745), with the results of two recently completed Phase IIa clinical trials that indicated significant Alzheimer's disease-relevant pharmacological activity.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news